Sutro Biopharma, Inc.
310 Utah Avenue
South San Francisco
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Sutro’s discovery and development efforts are driven by the Xpress CF™ platform, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro’s make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks, enabling broader and deeper biologics discovery and development efforts than can be accomplished with current cell-based expression technologies. Sutro’s technology platform allows production of proteins by bypassing the cell completely, cutting the pre-clinical development period by several months and can be done on any scale in just 8-10 hours.
Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.
In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics. Last year, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion. In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.
• William J. Newell, JD, CEO
• Trevor Hallam, PhD, Chief Scientific Officer
• Ed Albini, Chief Financial Officer
• Henry Heinsohn, VP Development & Manufacturing
• Aaron Sato, PhD, VP Research
• Nicki Vasquez, PhD, VP Alliance/Project Management
Interested in joining Sutro? Check us out on Linkedin @
66 articles with Sutro Biopharma, Inc.
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+™ cell-free protein synthesis technology.
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as Clinical Development Candidate
Sutro Biopharma, Inc. announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City.
Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
Sutro Biopharma, Inc. reported its financial results for the three and six months ended June 30, 2019.
Sutro Biopharma, Inc. announced that its Chief Business Officer, Stephen Worsley, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 13 at 1:20 p.m. EDT in New York City.
Former Biogen Idec executive to bring additional strategic expertise to Sutro's Board
Sutro Biopharma, Inc. announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 20 at 12:30 p.m. ET at the St.
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)
Sutro Biopharma, Inc. announced that the company will present at the upcoming European Hematology Association Congress being held June 13-16, 2019, in Amsterdam.
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
Sutro Biopharma, Inc. reported its financial results for the quarter ended March 31, 2019.
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York.
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers.
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston.
- Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company
Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St. Francis Hotel in San Francisco.
Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities
Sutro Biopharma, Inc. will present at the 30th Annual Piper Jaffray Healthcare Conference.
STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma